BBOT NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

BridgeBio Oncology Therapeutics, Inc. · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 8.82 USD
3.0% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -6.2% below the Trend Line and sits at 23.1% of its 52-week range. The latest completed week returned 3.0%, after a 19.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 42 out of 100
Latest Close 8.82 USD 24 Jul 2026
1W Return 3.0% latest completed week
4W Return 19.2% short-term follow-through
12W Return 5.1% quarterly tape
Trend Breadth 0.0% 0 of 50 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
  • Next-week expectancy is positive at 55.70% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.0% Latest completed week; four-week move 19.2%. Indicator stack 0/62 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 55.70% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 56/100 57 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -6.2% below the Trend Line and sits at 23.1% of its 52-week range. The latest completed week returned 3.0%, after a 19.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0512-week average 0.02

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.05Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 19.2% over four weeks, 5.1% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W3.0%
4W19.2%
12W5.1%
26W-30.1%
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.09Latest activity-pressure read.
Pressure change133.0%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 61% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength69/100Blend of value, momentum, and quality. Underlying universe rank 32; rank 1 is best.
Value59/100Relative valuation strength. Underlying universe rank 42; rank 1 is best.
Quality57/100Profitability and accounting quality. Underlying universe rank 44; rank 1 is best.
Momentum59/100Medium-term price momentum. Underlying universe rank 42; rank 1 is best.
Growth59/100Revenue and earnings growth. Underlying universe rank 42; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-26.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-39.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-3.1%
Net share repurchases relative to market value.
Shareholder yield
-3.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 57 relevant articles.

14 positive · 42 neutral · 1 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-40.7%Distance below the 52-week high.
13-week volatility6.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+11.3%Week of 17 Apr.
Worst week-12.9%Week of 5 Jun.
Latest week+3.0%Week of 24 Jul.

Shape of recent returns

Strong gains5
Modest gains8
Flat weeks0
Modest losses3
Sharp losses10
Recent vol6.4%13-week weekly-return volatility.
Base vol7.2%52-week weekly-return volatility.
Up/down split25/24Count of positive and negative weeks in the 52-week window.
Average skew5.6% / -6.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape33/100

Trend, activity pressure, participation, and risk combine to a 33/100 tape read.

 Indicator analysis14/100

Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.

Activity pressure 0.05; No reversal markers Next-Week ExpectancyPositive 55.70%

Next-week expectancy is positive with a 55.70% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 80; Small Cap Core rank 49 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment56/100

Weighted news tone is neutral across 57 relevant articles.

BridgeBio Oncology Therapeutics Ord Shs (BBOT) Shareholder Structure: Major Shareholders & Institutional Holdings Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20268.82 USD3.0%9.40 USD10.27 USD0.09-1.4MOff
17 Jul 20268.56 USD2.9%9.52 USD10.30 USD0.06-2.0MOff
10 Jul 20268.32 USD2.6%9.65 USD10.33 USD0.02-2.3MOff
3 Jul 20268.11 USD9.6%9.80 USD10.37 USD-0.13-1.5MOff
26 Jun 20267.40 USD-2.1%9.98 USD10.42 USD-0.26-3.3MOff
19 Jun 20267.56 USD-2.5%10.14 USD10.49 USD-0.27-3.7MOff
12 Jun 20267.75 USD-0.8%10.31 USD10.56 USD-0.37-1.6MOff
5 Jun 20267.81 USD-12.9%10.48 USD10.62 USD-0.42-898.5KOff
29 May 20268.97 USD4.9%10.63 USD10.69 USD-0.67-1.3MOff
22 May 20268.55 USD0.5%10.73 USD10.73 USD-0.97-2.9MOff
15 May 20268.51 USD11.1%10.81 USD10.79 USD-1.05-2.1MOff
8 May 20267.66 USD-8.7%10.90 USD10.84 USD-1.11-1.3MOff
1 May 20268.39 USD-4.4%11.04 USD10.93 USD-1.04-2.1MOff
24 Apr 20268.78 USD-6.1%11.17 USD11.00 USD-1.08-3.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.